Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PET ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States.Cancers (Basel). 2021; 13https://doi.org/10.3390/cancers13081753
- Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.Histopathology. 2017; 70: 412-422
WHO classification of Tumours Editorial Board, WHO classification of Tumours - Thoracic tumors, 5.
- Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.J Thorac Oncol. 2014; 9: 273-284
- CT features of peripheral pulmonary carcinoid tumors.AJR Am J Roentgenol. 2011; 197: 1073-1080
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.Ann Oncol. 2015; 26: 1604-1620
- The prognostic significance of the 8th edition TNM staging of pulmonary carcinoid tumors: a single institution study with long-term follow-up.Am J Surg Pathol. 2019; 43: 1291-1296
- Evaluation of the prognostic significance of TNM staging guidelines in lung carcinoid tumors.J Thorac Oncol. 2019; 14: 184-192
- Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.Ann Oncol. 2010; 21: 548-555
- 111In-Pentetreotide SPECT/CT in pulmonary carcinoid.Anticancer Res. 2015; 35: 4265-4270
- Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids.EJNMMI Res. 2015; 5: 53
- Diagnostic fficiency of (68)Ga-DOTATATE PET/CT as ompared to (99m)Tc-Octreotide SPECT/CT andonventional orphologic odalities in euroendocrine umors.Asia Ocean J Nucl Med Biol. 2019; 7: 129-140
- Performance of 68Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and 18F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis.Nucl Med Commun. 2020; 41: 370-376
- 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.J Nucl Med. 2016; 57: 872-878
- Value of [(68)Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature.EJNMMI Res. 2022; 12: 28
- FDG-PET imaging in patients with pulmonary carcinoid tumor.Clin Nucl Med. 2013; 38: 501-505
- The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: a systematic review and meta-analysis.Medicine (Baltimore). 2019; 98: e14769
- [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.Neoplasia. 2005; 7: 369-379
- Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis.Mod Pathol. 2009; 22: 633-638
- Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.Theranostics. 2017; 7: 1149-1158
- Clinical utility of (18)F-FDG PET in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis.Cancers (Basel). 2021; 13https://doi.org/10.3390/cancers13081813
- (18)F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study.J Nucl Med. 2021; 62: 808-815
- Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on (68)Ga-DOTATATE PET/CT and (18)F-FDG PET/CT.Eur J Nucl Med Mol Imaging. 2021; 48: 204-216
- Management of carcinoid tumors.Ann Thorac Surg. 2010; 89: 998-1005
- Adjuvant therapy for lung neuroendocrine neoplasms.World J Clin Oncol. 2021; 12: 664-674
- NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018.J Natl Compr Canc Netw. 2018; 16: 693-702
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med. 2014; 371: 224-233
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.J Clin Oncol. 2009; 27: 4656-4663
- Outcome analysis of first-line somatostatin analog treatment in metastatic pulmonary neuroendocrine tumors and prognostic significance of (18)FDG-PET/CT.Clin Lung Cancer. 2017; 18: 415-420
- Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.Eur J Cancer. 2017; 75: 259-267
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.Lancet. 2016; 387: 968-977
- Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.Cancer Sci. 2018; 109: 174-181
- Peptide receptor radionuclide therapy and the treatment of gastroentero-pancreatic neuroendocrine tumors: current findings and future perspectives.Nucl Med Mol Imaging. 2018; 52: 190-199
- NANETS/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy.J Nucl Med. 2020; 61: 222-227
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2013; 40: 800-816
- Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors.N Engl J Med. 2017; 376: 125-135
- (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol. 2021; 22: 1752-1763
- Efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Am J Nucl Med Mol Imaging. 2017; 7: 74-83
- Clinical response profile of metastatic/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with 177Lu-DOTATATE.Clin Nucl Med. 2017; 42: 428-435
- Long-Term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors.Clin Cancer Res. 2017; 23: 4617-4624
- Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).Lung Cancer. 2020; 150: 70-75
Article info
Publication history
Published online: December 28, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
